Azole antifungals: 35 years of invasive fungal infection management

References

• Marr KA. Invasive Candida infections: the changing epidemiology. Oncology 2004;18(14 Suppl 13):9-14
   PubMedGoogle Scholar
• Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol 2013;8(9):1163-75
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infecti Dis 2012;54(Suppl 1):S23-34
   PubMed Web of Science ®Google Scholar
• Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980;302(3):145-55
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50(3):291-322
   PubMed Web of Science ®Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12(1):40-79
   PubMed Web of Science ®Google Scholar
• Shadomy S. In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun 1971;4(2):143-8
   PubMed Web of Science ®Google Scholar
• Sawyer PR, Brogden RN, Pinder RM, et al. Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1975;9(6):424-47
   PubMed Web of Science ®Google Scholar
• Heel RC, Brogden RN, Pakes GE, et al. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 1980;19(1):7-30
   PubMed Web of Science ®Google Scholar
• Bennett JE, Remington JS. Miconazole in cryptococcosis and systemic candidiasis: a word of caution. Ann Intern Med 1981;94(5):708-9
   PubMed Web of Science ®Google Scholar
• Lutwick LI, Rytel MW, Yanez JP, et al. Deep infections from Petriellidium boydii treated with miconazole. JAMA 1979;241(3):272-3
   PubMed Web of Science ®Google Scholar
• Graybill JR. Antifungal agents used in systemic mycoses: activity and therapeutic use. Drugs 1983;25(1):41-62
   PubMed Web of Science ®Google Scholar
• Fainstein V, Bodey GP. Cardiorespiratory toxicity due to miconazole. Ann Intern Med 1980;93(3):432-3
   PubMed Web of Science ®Google Scholar
• Heel RC, Brogden RN, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23(1-2):1-36
   PubMed Web of Science ®Google Scholar
• Van Der Meer JW, Keuning JJ, Scheijgrond HW, et al. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother 1980;6(4):552-4
   PubMed Web of Science ®Google Scholar
• Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984;86(3):503-13
   PubMed Web of Science ®Google Scholar
• Yan JY, Nie XL, Tao QM, et al. Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis. Biomed Environ Sci 2013;26(7):605-10
   PubMed Web of Science ®Google Scholar
• Gupta AK, Daigle D, Foley KA. Drug safety assessment of oral formulations of ketoconazole. Expert Opin Drug Saf 2015;14(2):325-34
   PubMed Web of Science ®Google Scholar
• Pont A, Williams PL, Loose DS, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982;97(3):370-2
   PubMed Web of Science ®Google Scholar
• Galsky MD, Simon K, Sonpavde G, et al. Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol 2009;20(5):965-6
   PubMed Web of Science ®Google Scholar
• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10(Suppl 1):1-10
   PubMed Web of Science ®Google Scholar
• Drouhet E, Dupont B. Chronic mucocutaneous candidosis and other superficial and systemic mycoses successfully treated with ketoconazole. Rev Infect Dis 1980;2(4):606-19
   PubMedGoogle Scholar
• FDA Drug Safety Communication. FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems, 2013. Available from: www.fda.gov/Drugs/DrugSafety/ucm362415.htm
   Google Scholar
• Rotta I, Otuki MF, Sanches AC, Correr CJ. Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis. Rev Assoc Med Bras 1992;58(3):308-18
   Google Scholar
• Diflucan [package insert]. Pfizer, New York, NY; March 2013. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=575
   Google Scholar
• Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992;117(8):655-60
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23(5):964-72
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171(6):1545-52
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
   PubMed Web of Science ®Google Scholar
• Sporanox [package insert]. Janssen-Cilag Pty Ltd; Macquarie Park, Australia: November 2014. Available from: www.janssen.com.au/files/Products/Sporanox_Capsules_PI.pdf
   Google Scholar
• Sporanox [package insert]. Janssen-Cilag Pty Ltd; Macquarie Park, Australia: November 2014. Available from: www.janssen.com.au/files/Products/Sporanox_Solution_PI.pdf
   Google Scholar
• Dolton MJ, McLachlan AJ. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Curr Opin Infect Dis 2014;27(6):493-500
   PubMed Web of Science ®Google Scholar
• Pound MW, Townsend ML, Dimondi V, et al. Overview of treatment options for invasive fungal infections. Med Mycol 2011;49(6):561-80
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Iinfect Dis 2007;45(7):807-25
   PubMed Web of Science ®Google Scholar
• Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008;46(12):1801-12
   PubMed Web of Science ®Google Scholar
• Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997;157(16):1857-62
   PubMedGoogle Scholar
• Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 2009;168(6):313-27
   PubMed Web of Science ®Google Scholar
• Lass-Florl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 2011;71(18):2405-19
   PubMed Web of Science ®Google Scholar
• Diekema D, Arbefeville S, Boyken L, et al. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 2012;73(1):45-8
   PubMed Web of Science ®Google Scholar
• Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008;59:361-79
   PubMed Web of Science ®Google Scholar
• De Sarro A, La Camera E, Fera MT. New and investigational triazole agents for the treatment of invasive fungal infections. J Chemother 2008;20(6):661-71
   PubMed Web of Science ®Google Scholar
• Vfend [package insert]. Pfizer; New York, NY: February 2014. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=618
   Google Scholar
• Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4(3):457-68
   PubMedGoogle Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36(9):1122-31
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010;54(10):4446-50
   PubMed Web of Science ®Google Scholar
• Thompson GR3rd, Lewis JS2nd. Pharmacology and clinical use of voriconazole. Expert Opin Drug Metab Toxicol 2010;6(1):83-94
   PubMed Web of Science ®Google Scholar
• Obeng A EE, Alsultan A, Peloquin C, Johnson J. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy 2014;34(7):703-18
   PubMed Web of Science ®Google Scholar
• Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011;52(5):604-11
   PubMed Web of Science ®Google Scholar
• Malani AN, Kerr L, Obear J, et al. Alopecia and nail changes associated with voriconazole therapy. Clin Infect Dis 2014;59(3):e61-5
   PubMed Web of Science ®Google Scholar
• Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014;58(7):997-1002
   PubMed Web of Science ®Google Scholar
• Noxafil [package insert]. Merck & Co., Inc; Whitehouse Station, NJ: June 2014. Available from: www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf
   Google Scholar
• Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Infect Dis 2010;14(Suppl 3):e100-3
   PubMed Web of Science ®Google Scholar
• Cornely OA, Helfgott D, Langston A, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother 2012;56(5):2652-8
   PubMed Web of Science ®Google Scholar
• Green MR, Woolery JE. Optimising absorption of posaconazole. Mycoses 2011;54(6):e775-9
   Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, O’Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012;56(8):4196-201
   PubMed Web of Science ®Google Scholar
• Kraft WK, Chang PS, van Iersel ML, et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 2014;58(7):4020-5
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12
   PubMed Web of Science ®Google Scholar
• Van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42(7):e61-5
   PubMed Web of Science ®Google Scholar
• Johnson MD, Perfect JR. Use of antifungal combination therapy: agents, order, and timing. Curr Fungal Infect Rep 2010;4(2):87-95
   PubMedGoogle Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012;54(8):1110-22
   PubMed Web of Science ®Google Scholar
• Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012;10(11):1412-45
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. 2008;46(3):327-60
   Google Scholar
• Perfect JR, Hachem R, Wingard JR. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. Clin Infect Dis 2014;59(Suppl 5):S352-5
   PubMedGoogle Scholar
• Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 2014;20(Suppl 3):27-46
   PubMed Web of Science ®Google Scholar
• Kim JH, Williams K. Posaconazole salvage treatment for invasive fungal infection. Mycopathologia 2014;178(3-4):259-65
   PubMed Web of Science ®Google Scholar
• Drew RH, Townsend ML, Pound MW, et al. Recent advances in the treatment of life-threatening, invasive fungal infections. Expert Opin Pharmacother 2013;14(17):2361-74
   PubMed Web of Science ®Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014;69(5):1162-76
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Mouton JW, Verweij PE, Bruggemann RJ. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther 2013;11(9):931-41
   PubMed Web of Science ®Google Scholar
• Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012;55(8):1080-7
   PubMed Web of Science ®Google Scholar
• Vaes M, Hites M, Cotton F, et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother 2012;56(12):6298-303
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56(6):2806-13
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015;162(2):81-9
   PubMed Web of Science ®Google Scholar
• Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis 2014;28c:80-94
   Google Scholar
• Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica 2013;98(10):e127-30
   PubMed Web of Science ®Google Scholar
• Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist 2013;6:163-74
   PubMedGoogle Scholar
• Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50(1):279-85
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 2009;53(11):4885-90
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J antimicrob Chemother 2008;61(Suppl 1):i19-30
   PubMed Web of Science ®Google Scholar
• Maertens J, Patterson T, Rahav G, et al. A phase 3 randomised, double-blind trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other. filamentous fungi (SECURE). European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain; May 10–13, 2014; Poster presentation, O230a
   Google Scholar
• Patterson T, Selleslag D, Mullane K, et al. A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in neutropenic patients. ID Week, Pennsylvania, Philadelphia; October 8–12, 2014; Poster presentation, 109-AB
   Google Scholar
• Raad I, Mullane I, Selleslag D, et al. A Phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole vs. voriconazole in patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections. IDWeek, Pennsylvania, Philadelphia; October 8–12, 2014; Poster presentation, 109-AB
   Google Scholar
• Kontoyiannis D, Giladi M, Lee M, et al. A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in invasive aspergillosis patients. ID Week, Pennsylvania, Philadelphia; October 8–12, 2014; Poster presentation, 109-AB
   Google Scholar
• Khandelwal N, Franks B, Shi F, et al. Health economic outcome analysis of patients randomized in the SECURE phase 3 trial comparing isavuconazole to voriconazole for primary treatment of invasive fungal disease caused by aspergillus species or other filamentous fungi. ID Week, Pennsylvania, Philadelphia; October 8–12, 2014; Poster presentation 827
   Google Scholar
• Marty FM, Perfect JR, Cornely OA, et al. An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis. ID Week, Pennsylvania, Philadelphia; October 8–12, 2014; Poster presentation, Hall BC
   Google Scholar
• Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in Patients with Invasive Mold Disease Caused by Fusarium or Scedosporium spp. Treated with Isavuconazole: Experience from the VITAL and SECURE Trials. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Wasington, DC; September 5–9, 2014; Abstract M-1760
   Google Scholar
• U.S. National Institutes of Health. Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections. ClinicalTrials.gov Identifier: NCT00413218. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT00413218?term=isavuconazole&rank=26
   Google Scholar
• Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2006;44(5):1782-7
   PubMed Web of Science ®Google Scholar
• Olsen SJ, Mummaneni V, Rolan P, et al. Ravuconazole single ascending oral dose study in healthy subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Canada, Toronto; September 17–20, 2000; Abstract 838
   Google Scholar
• Marino MR, Mummanei V, Norton J, et al. Ravuconazole exposure-response relationship in HIV-patients with oropharyngeal candidiasis. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Illinois, Chicago; December 16–19, 2001; Abstract J-1622
   Google Scholar
• Gupta AK, Leonardi C, Stoltz RR, et al. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005;19(4):437-43
   PubMed Web of Science ®Google Scholar
• Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents chemother 2001;45(9):2635-7
   PubMed Web of Science ®Google Scholar
• Dietz AJ, Barnard JC, van Rossem K. A randomized, double-blind, multiple-dose, placebo-controlled, dose escalation study with a 3-cohort parallel group design to investigate the tolerability and pharmacokinetics of albaconazole in healthy subjects. Clinical Pharmacology in Drug Development 2014;3(1):25-33
   PubMed Web of Science ®Google Scholar
• van Rossem K, Lowe JA. A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation. Clin Pharmacol 2013;5:23-31
   PubMedGoogle Scholar
• Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol 2013;69(3):416-25
   PubMed Web of Science ®Google Scholar
• Bartroli X, Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. Interscience Conference on Antimicriobial Agents and Chemotherapy (ICAAC), Washington, DC; December 16–19, 2005; Abstract M-722
   Google Scholar
• Urbina JA, Payares G, Sanoja C, et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003;21(1):27-38
   PubMed Web of Science ®Google Scholar
• Guedes PM, Urbina JA, de Lana M, et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother 2004;48(11):4286-92
   PubMed Web of Science ®Google Scholar
• Hoekstra WJ, Garvey EP, Moore WR, et al. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett 2014;24(15):3455-8
   PubMed Web of Science ®Google Scholar
• Warrilow AG, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother 2014;58(12):7121-7
   PubMed Web of Science ®Google Scholar